These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25184175)

  • 41. Efficacy and safety of oral direct factor Xa inhibitors versus warfarin in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
    Xiang CL; Gong YZ; Zeng LJ; Wang R; Kea S; Chaudhary N; Tu RH; He Y
    Acta Cardiol; 2016 Jun; 71(3):349-57. PubMed ID: 27594130
    [No Abstract]   [Full Text] [Related]  

  • 42. [Oral anticoagulation with Edoxaban for stroke prevention in patients with atrial fibrillation: Analysis of 1-year follow-up data of routine clinical practice in Germany, Austria and Switzerland (DACH) from the ETNA-AF registry].
    Dinshaw L; Steffel J; Götte A; Weiss TW; Waltenberger J; Kirchhof P
    Dtsch Med Wochenschr; 2024 Aug; 149(15):e58-e66. PubMed ID: 38959945
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
    Morishima Y; Kamisato C; Honda Y
    Eur J Pharmacol; 2014 Nov; 742():15-21. PubMed ID: 25179572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. AParadigm Shift: The New Novel Oral Anticoagulation Agents.
    Saeed W; Burke JF; Mirrani G; Sirinivasa M; Nabi U; Hayat U; Khan Z; Sardar MR
    J Coll Physicians Surg Pak; 2016 Jul; 26(7):611-9. PubMed ID: 27504556
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program.
    Chao TF; Hong KS; Lee BC; De Caterina R; Kirchhof P; Reimitz PE; Chen C; Unverdorben M; Wang CC
    J Chin Med Assoc; 2021 May; 84(5):485-490. PubMed ID: 33742992
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
    Spencer RJ; Amerena JV
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
    Salazar DE; Mendell J; Kastrissios H; Green M; Carrothers TJ; Song S; Patel I; Bocanegra TS; Antman EM; Giugliano RP; Kunitada S; Dornseif B; Shi M; Tachibana M; Zhou S; Rohatagi S
    Thromb Haemost; 2012 May; 107(5):925-36. PubMed ID: 22398655
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
    Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
    Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Edoxaban (Savaysa)--the fourth new oral anticoagulant.
    Med Lett Drugs Ther; 2015 Mar; 57(1465):43-5. PubMed ID: 25853577
    [No Abstract]   [Full Text] [Related]  

  • 50. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
    Marcy TR; Truong T; Rai A
    Consult Pharm; 2015 Nov; 30(11):644-56. PubMed ID: 26629800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.
    Morishima Y; Honda Y; Kamisato C; Tsuji N; Kita A; Edo N; Shibano T
    Thromb Res; 2012 Sep; 130(3):514-9. PubMed ID: 22647432
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Edoxaban: Review of pharmacology and key phase I to III clinical trials.
    Plitt A; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Sep; 19(5):409-16. PubMed ID: 24607764
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials.
    Loffredo L; Perri L; Violi F
    Dig Liver Dis; 2015 May; 47(5):429-31. PubMed ID: 25732432
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Edoxaban (Lixiana°).
    Prescrire Int; 2017 Jan; 26(178):13-14. PubMed ID: 30730636
    [No Abstract]   [Full Text] [Related]  

  • 56. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of Oral Anticoagulants According to the Degree of Renal Impairment in Japanese Patients With Atrial Fibrillation--Which Non-Vitamin K Antagonist Oral Anticoagulant to Select?
    Ikeda T
    Circ J; 2015; 79(7):1441-3. PubMed ID: 26028323
    [No Abstract]   [Full Text] [Related]  

  • 58. Oral anticoagulants for stroke prevention in atrial fibrillation.
    Senoo K; Lane DA; Lip GY
    Curr Probl Cardiol; 2014 Sep; 39(9):319-44. PubMed ID: 25194766
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.
    Piccini JP; Garg J; Patel MR; Lokhnygina Y; Goodman SG; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Nessel CC; Mahaffey KW; Singer DE; Califf RM; Fox KA;
    Eur Heart J; 2014 Jul; 35(28):1873-80. PubMed ID: 24658769
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Edoxaban and the need for outcomes-based NOAC dosing.
    Patel MR; Washam JB
    Lancet; 2015 Jun; 385(9984):2232-3. PubMed ID: 25769359
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.